PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30797591-9	2019	Pre-clinically, ERCC1 or XPF depletion not only increased platinum sensitivity but also increased toxicity to Olaparib therapy.	olaparib	110-118	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	16-21	
23275151-5	2013	Drug combination experiments revealed that two distinct PARP inhibitors, olaparib and veliparib, not only potentiated the cell killing by cisplatin but also conferred cytotoxicity as a single agent specifically in ERCC1-low HCC827 and PC9 but not in ERCC1-high A549 and H157 lung cancer cells.	olaparib	73-81	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	214-219	
23275151-5	2013	Drug combination experiments revealed that two distinct PARP inhibitors, olaparib and veliparib, not only potentiated the cell killing by cisplatin but also conferred cytotoxicity as a single agent specifically in ERCC1-low HCC827 and PC9 but not in ERCC1-high A549 and H157 lung cancer cells.	olaparib	73-81	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	250-255	
23275151-6	2013	Moreover, small interfering RNA knockdown of ERCC1 in A549 and H157 cells increased their sensitivities to both cisplatin and olaparib in a synergistic manner in our model.	olaparib	126-134	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	45-50	
33747222-9	2021	In NCI-H1299 or SK-MES-1 cells treated with cisplatin combined with olaparib for 24 h, the cell viability significantly increased following ERCC1 overexpression compared with the GV230 group (P<0.05), but significantly inhibited following ERCC1 knockdown compared with the siRNA-NC group (P<0.05).	olaparib	68-76	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	140-145	
33747222-9	2021	In NCI-H1299 or SK-MES-1 cells treated with cisplatin combined with olaparib for 24 h, the cell viability significantly increased following ERCC1 overexpression compared with the GV230 group (P<0.05), but significantly inhibited following ERCC1 knockdown compared with the siRNA-NC group (P<0.05).	olaparib	68-76	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	239-244	
30797591-11	2019	CONCLUSION: The data provide evidence that low ERCC1 is not only a predictor of platinum sensitivity but is also a promising biomarker for Olaparib induced synthetic lethality in ovarian cancers.	olaparib	139-147	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	47-52	
30589644-4	2019	We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells.	olaparib	47-55	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	123-128